Newsroom
Sorted by: Latest
-
Les entreprises européennes se tournent vers les clouds souverains pour renforcer leur conformité et leur résilience
LONDRES--(BUSINESS WIRE)--Les entreprises européennes accélèrent l’adoption de solutions cloud souveraines afin de répondre à des réglementations de plus en plus strictes, à la montée des risques géopolitiques et aux exigences accrues en matière de souveraineté et de transparence des données, selon un nouveau rapport publié aujourd’hui par Information Services Group (ISG) (Nasdaq : III), cabinet mondial de conseil et de recherche en technologies axées sur l’intelligence artificielle. Le rapport...
-
China Carbides Market Business Report 2025: PESTEL Analysis, Producers and Product Range, Export and Import, Major Wholesalers and Trading Companies, Consumers - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Carbides Market in China: Business Report 2025" report has been added to ResearchAndMarkets.com's offering. The report presents analysis of the carbides market in China. Scope Brief country profile includes general information and main economic indicators and specifies business environment in China Carbides market is analyzed by different parameters including domestic production and consumption. Future market development is also estimated Trade analysis covers data...
-
Metropolitan Bank Holding Corp. Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call Dates
NEW YORK--(BUSINESS WIRE)--Metropolitan Bank Holding Corp. (the “Company”) (NYSE: MCB), the holding company for Metropolitan Commercial Bank, today announced it will release fourth quarter and full year 2025 financial results after the market closes on Tuesday, January 20, 2026. The Company will conduct a conference call at 9:00 a.m. ET on Wednesday, January 21, 2026, to discuss the results. To access the event by telephone, please dial 800-245-3047 (US), 203-518-9765 (INTL), and provide confer...
-
India Cyanides (Cyanide Oxides and Complex Cyanides) Market Business Report 2025: PESTEL Analysis, Producers and Product Range, Export and Import, Major Wholesalers and Trading Companies, Consumers - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Cyanides, Cyanide Oxides and Complex Cyanides Market in India: Business Report 2025" report has been added to ResearchAndMarkets.com's offering. The report presents analysis of the cyanides, cyanide oxides and complex cyanides market in India. Scope Brief country profile includes general information and main economic indicators and specifies business environment in India Cyanides, Cyanide Oxides and Complex Cyanides market is analyzed by different parameters includ...
-
Securities Fraud Investigation Into Ardent Health, Inc. (ARDT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ARDENT HEALTH, INC. (ARDT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On November 12, 2025, after market hours, Ardent released its third...
-
Deadline Soon: Stride, Inc. (LRN) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 12, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) securities between October 22, 2024 and October 28, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRIDE, INC. (LRN), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD...
-
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Varonis Systems, Inc. (VRNS) Shareholders To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Varonis Systems, Inc. (“Varonis” or the “Company”) (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, inclusive (the “Class Period”). Varonis investors have until March 9, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON...
-
Nashville’s Anzie Blue and Honda Powersports Wrap 2025 With Global New Year’s Eve, Star-studded Musical Event Highlighting the Best of Music City
NASHVILLE, Tenn.--(BUSINESS WIRE)--The spirit of Music City was on full display on New Year’s Eve as indie music venue Anzie Blue and Honda Powersports partnered to present Anzie Blue New Year’s Eve Live, a first-time musical event featuring a genre-spanning lineup that was seen worldwide. The six-hour event was livestreamed on CNN.com, with select performances airing live on CNN as part of its daytime coverage of New Year’s Eve from cities around the world. Hosted by CNN anchor Lynda Kinkade,...
-
Deadline Soon: Freeport-McMoran Inc. (FCX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 12, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX) securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON FREEPORT-MCMORAN INC. (FCX), CLICK HERE TO PARTICIPATE I...
-
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an e...